Press release
Chronic Hepatitis B Market Expansion Continues, with Forecast Valuation of $4.59 Billion by 2029
Chronic Hepatitis B
Chronic Hepatitis B Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market associated with chronic hepatitis b has experienced consistent expansion lately; projections indicate a rise from $3.77 billion in 2024 to $3.93 billion the subsequent year, reflecting a compound annual growth rate (CAGR) of 4.2%. This upward trajectory throughout the historical timeframe stems from several factors, including progress in treatments utilizing antiviral agents, expanding promotional efforts by governmental bodies and non-governmental organizations, enhancements in methods for disease detection, the increasing incidence of HIV infections, and greater public consciousness about the condition.
Chronic Hepatitis B Market Size Forecast: What's the Projected Valuation by 2029?
Projections indicate that the market for chronic hepatitis B will experience consistent expansion over the coming years, reaching a value of $4.59 billion by 2029, driven by an anticipated compound annual growth rate (CAGR) of 4.0%; this upward trajectory is underpinned by factors such as the penetration into nascent regions, increased allocation of resources and supportive governmental legislation, advancements in identifying and testing for the condition, escalating healthcare spending, a rise in strategic alliances and cooperative agreements, the societal trend of an increasing median age, and widespread public education initiatives, while key market developments moving forward will involve a pivot towards treatments offering complete cures, further development in developing economies, upgrades in diagnostic capabilities and early detection methods, the formation of new alliances, and an intensified emphasis on care models tailored to individual patient needs.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
What Are the Drivers Transforming the Chronic Hepatitis B Market?
Anticipated expansion in the sheer
volume of chronic hepatitis B cases is set to fuel the advancement of the market dedicated to this condition. Hepatitis B represents a liver ailment caused by the hepatitis B virus (HBV), which fortunately has a preventative vaccine available. A confluence of elements contributes to the escalating incidence of hepatitis B, particularly within nations categorized as low- and middle-income, where insufficient vaccination uptake results in elevated transmission risks because substantial segments of the population lack immunity. Surging numbers of hepatitis B infections naturally precipitate a greater need for both detection methods and therapeutic interventions. To illustrate this, data released in June 2024 by the Centers for Disease Control and Prevention (CDC), an agency of the United States government, suggested that achieving 90% global vaccination coverage against hepatitis B and ensuring 80% access to treatment could avert 26 million new infections and 9 million fatalities linked to hepatitis B between 2022 and 2050. Moreover, the year 2022 saw 1.2 million newly diagnosed cases of HBV infection; consequently, the widespread nature of hepatitis B infection serves as the primary impetus for growth within the chronic hepatitis B virus market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp
What Long-Term Trends Will Define the Future of the Chronic Hepatitis B Market?
Leading firms within the chronic hepatitis B landscape are concentrating their efforts on progressing technology, notably through the introduction of new antiviral treatments; these innovative pharmaceutical agents function by obstructing viral reproduction and employing sophisticated delivery mechanisms, explicitly aiming at difficult-to-treat infections, with several molecules currently undergoing rigorous assessment for both safety and therapeutic impact, one such example being bepirovirsen directed against chronic hepatitis B. Reflecting this development, GSK plc, the multinational healthcare giant headquartered in the UK with expertise spanning research, production, and sales across numerous health sectors, secured the U.S. Food and Drug Administration's Fast Track status in February 2024 for bepirovirsen, an experimental antisense oligonucleotide therapeutic intended for chronic hepatitis B (CHB) management; this therapeutic agent is engineered specifically to locate and eliminate the messenger RNA of the hepatitis B virus (HBV), consequently offering the potential for the body's natural defenses to reassert command over the persistent infection, building upon encouraging data from its Phase IIb evaluations, notably the B-Clear and B-Sure investigations, which confirmed its capability in lowering levels of hepatitis B surface antigen (HBsAg) and sustaining viral suppression over time.
Which Segments in the Chronic Hepatitis B Market Offer the Most Profit Potential?
The chronic hepatitis bmarket covered in this report is segmented -
1) By Drug Class: Antivirals; Immune Modulators
2) By Gender: Male; Female
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp
Which Firms Dominate the Chronic Hepatitis B Market by Market Share and Revenue in 2025?
Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals
Which Regions Offer the Highest Growth Potential in the Chronic Hepatitis B Market?
North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Market Expansion Continues, with Forecast Valuation of $4.59 Billion by 2029 here
News-ID: 4275182 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
